neo-gambogic acid has been researched along with erlotinib hydrochloride in 1 studies
| Studies (neo-gambogic acid) | Trials (neo-gambogic acid) | Recent Studies (post-2010) (neo-gambogic acid) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
|---|---|---|---|---|---|
| 63 | 0 | 59 | 4,353 | 786 | 3,033 |
| Protein | Taxonomy | neo-gambogic acid (IC50) | erlotinib hydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, W; Lao, Y; Li, X; Meng, X; Qian, J; Tan, H; Tu, S; Xu, H; Xu, L; Xu, N; Zhang, L; Zhou, Q | 1 |
1 other study(ies) available for neo-gambogic acid and erlotinib hydrochloride
| Article | Year |
|---|---|
Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Signal Transduction; Tumor Burden; Xanthenes; Xenograft Model Antitumor Assays | 2018 |